Podcasts about novartis pharmaceuticals

Hey, friend. Hello, Change Makers. In the words of Dr. Rikesha Fry Brown—Hey, Black girl. We often say it takes a village, but let's be clear—villages don't build themselves. They're shaped, sustained, and often revived by Black mothers who know what it means to care, connect, and carry more than their share. Today's guest, Jetaun Woodley, didn't just recognize the gap—she built something from it. As a veteran communications strategist and Senior Director at Planned Parenthood, Jetaun has spent her career making sure messages that matter reach the right people. But it's her work outside the boardroom that's building legacy: creating H.U. Mommies, a thriving community of over 800 Hamptonian mothers who show up for one another, online and in real life. In this episode, we're unpacking how Black motherhood is often the foundation of community organizing, mutual care, and everyday advocacy. From navigating health care systems and education challenges to disaster relief and doula recommendations, these mothers are doing far more than sharing parenting tips—they're reshaping what support looks like. Jetaun joins Dr. Rikesha Fry Brown and me for a conversation that's both grounding and galvanizing. We talk about the power of peer support, the courage it takes to create a space when one doesn't exist, and what it looks like to protect and evolve a community you've built—especially when the work is personal. If you've ever questioned whether your care counts or whether creating something small could really matter, this conversation is your reminder: it already does. Listen now and be sure to grab the National Black Girl Month™ Toolkit for more ways to connect at nationalblackgirlmonth.com. To our Hampton fam—we see you. And if you're a mama looking for your people, you just might find them in H.U. Mommies. Connect with Jetaun Woodly on Instagram Jetaun Woodly is an award winning public relations and brand communications strategist with 20 years of experience. She has an unwavering passion and focus on working with individuals and companies to translate business goals and objectives into strategic communications plans and deliverables. Jetaun started her career as a public relations coordinator for Novartis Pharmaceuticals' philanthropy and community development division. She spent many years working in healthcare managing public relations for brands ranging from prescription drugs and FDA approvals, to eye care and over-the-counter products before moving to the nonprofit sector. Currently, Jetaun serves as Senior Director of Brand Strategy & Projects at Planned Parenthood Federation of America, a reproductive health care nonprofit organization. Prior to joining PPFA, Jetaun served as Director of Network Marketing & Communications for National Court Appointed Special Advocate/Guardian ad Litem (CASA/GAL) Association for Children, a non-profit organization that supports and promotes court-appointed volunteer advocacy so every child who has experienced abuse or neglect can be safe, have a permanent home, and the opportunity to thrive. Following the birth of her son in 2015, Jetaun started HU Mommies Group - a support group for Hampton University alumnae. The goal of the group is to share advice, empower Black women, and provide a listening ear as Hamptonians embrace and embark on their motherhood journey. With more than 800 members, the group has planned a number of volunteer efforts across the country, vision board meetups, kid-friendly outings, tailgates at homecoming and a host of other activities. For example, when Hurricane Harvey hit Houston in 2017, Jetaun coordinated a group donation to local organizations that support mothers and children. In 2019, the group collectively donated to Hampton University's marching band, and sent care packages to current students. In an effort to provide unique learning experiences for the children of alumnae during the nationwide shelter-in-place (COVID19), Jetaun created virtual learning classes on a variety of subjects. Jetaun was featured on Essence Magazine Online for her work with the group. In 2020, Jetaun was admitted into Hampton University's Forty Under 40 Alumni Recognition Society. Jetaun served as a volunteer for the I Have a Dream Foundation - a mentor program in partnership with Ebenezer Baptist Church and St. Luke's Church in the heart of Atlanta. She is currently a board member of Atlanta Birth Center, a birth center dedicated to empowering families and providing compassionate, individualized birth experiences. A native of New Jersey, Jetaun received a Bachelor of Arts in Public Relations from Hampton University's Scripps Howard School of Journalism and Communications in 2004. While at Hampton, Jetaun was involved in Student Union Board and served as historian for the National Council of Negro Women. She also holds a Masters in Communication & Leadership from Gonzaga University in Spokane, Washington. Jetaun resides in Metro Atlanta with her husband, Dr. Shaun Woodly (HU '04), and their two children - Brayden and Brooklynn.

Novartis Pharmaceuticals Corporation v. Torrent Pharma Inc.

Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals, Inc.

Join us for an enlightening conversation as we sit down with Anthony Masiello, a seasoned healthcare veteran with over 25 years of experience. Anthony's journey began in the 90s at the prestigious National Institutes of Health (NIH), where he contributed to groundbreaking research for the Human Genome Project. His passion for innovation led him to Research and Development at Novartis Pharmaceuticals, where he sought to pioneer new therapies for disease.  But Anthony's path took a profound turn when he embarked on his own health transformation. Faced with obesity, hypertension, and a myriad of other health issues, he discovered the transformative power of whole food plant-based nutrition. Through dedication and lifestyle changes, Anthony not only shed 160 pounds but also reversed all his health conditions and has remained healthy ever since.  Today, Anthony is dedicated to revolutionizing healthcare by championing lifestyle medicine and whole food plant-based nutrition. As the former CEO of Plant Based TeleHealth, he spearheaded efforts to provide accessible medical services focused on disease prevention and reversal. Now, as part of Love.Life, a leading network of wellness hubs, Anthony continues to drive the convergence of food, medicine, and wellness for transformative health experiences.  In this captivating podcast episode, Anthony opens up about his personal health journey, from struggling with obesity and chronic illnesses to reclaiming his vitality and longevity. Reflecting on societal shifts in diet and health, Anthony shares pivotal moments that led to his profound lifestyle change and ultimate wellness.  Don't miss this empowering conversation as Anthony Masiello shares his insights and experiences, inspiring us all to take charge of our health and well-being. Tune in now and embark on your own journey of healing and empowerment!    Find Anthony Masiello and Love Life Telehealth at: Website: love.life/telehealth/ Facebook: @lovelifetelehealth YouTube: @lovelifetelehealth Instagram: @Amasiello  Discussed on the PODCAST: Book - Eat to Live – Dr Joel Fuhrman – https://a.co/d/gFPuz4h  Dr Neal Bernard - www.pcrm.org T. Colin Campbell – www.nutritionstudies.org Chef AJ – www.chefaj.com Dr Esselstyne - www.dresselstyn.com ERTH Podcast Ep 78 Eric Adams - www.greenmoustache.com/eat-real-to-heal-podcast/78 The Human Genome Project - www.genome.gov/human-genome-project Dr Micheal Klapper - www.doctorklaper.com Mastering Diabetes - www.masteringdiabetes.org Esalen Institute - www.esalen.org  Learn More: Are you a yoga instructor, health coach, nutritionist or health care worker? Learn more about our 6-Month Training Program to a certified Metabolic Nutrition & Detox Instructor!: https://bit.ly/3QiWzVj  Watch our award winning short documentary Grounded In My Roots - https://www.groundedinmyroots.com/  Find out more about our Charity- Sea to Sky Thrivers - https://bit.ly/S2STS  Want to know more about Nicolette's Green Moustache Café's https://bit.ly/GMCafeW  Sign up for the Eat Real to Heal Online Course - https://www.richerhealth.ca/  Buy the Eat Real to Heal Book here: https://bit.ly/4b7mzLa  

Guest: Dr. Howard Berman CEO and Chairman of Coya Therapeutics $COYA Website: https://coyatherapeutics.com/ Bio: Chief Executive Officer and Chairman of the Board Howard co-founded Nicoya Health in 2020 to realize the vision and research of Dr. Stanley Appel and merged the company with Coya Therapeutics in 2021 where he currently serves as Chairman and CEO. He has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify, and bridge both disciplines. Howard gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie where he spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and later Eli Lilly where he was the scientific point of contact between the company and key opinion leaders for development and initiation of collaborations, clinical trials and investigator initiated trials. Howard began his career at MD Anderson Cancer Center in the technology transfer division where he was responsible for assessing the market, patent, and scientific merits of numerous oncology-based technology platforms in order to ascertain their commercial viability He received a Bachelor in Biology from the University of Michigan and a Masters and Ph.D. in Neuroscience and Pharmacology from Weill Cornell Medical School. --- Support this podcast: https://podcasters.spotify.com/pod/show/smartmoneycircle/support

In this episode, Ayesha spoke with Howard Berman, PhD, Founder and CEO of Coya Therapeutics, a clinical-stage biotech company developing regulatory T cell (Treg) therapies targeting neurodegenerative, autoimmune and metabolic diseases. Dr. Berman founded Coya Therapeutics in 2021. Dr. Berman has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify and bridge both disciplines.Dr. Berman gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie where he spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and Eli Lilly.Dr. Berman received a Bachelor in Biology from the University of Michigan and a Masters and PhD in Neuroscience and Pharmacology from Weill Cornell Medical School.Tune into the episode to learn more about Coya Therapeutics and its Treg-targeted therapies program. The company's current pipeline includes its lead candidate product COYA 302, which is currently being evaluated in a clinical study for the treatment of amyotrophic lateral sclerosis (ALS). For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/  Follow Us on Social MediaTwitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Erin Krolikiewicz, Global Head of Precision Talent at Novartis Pharmaceuticals, shared the story behind her title with us on March 20, 2024.As the Global Head of Precision Talent and Executive Scouting at Novartis, Erin leads a cross-divisional and cross-unit team of talent professionals with a focus on executive advisory and community of practice for internal and external talent strategies.With over 20 years of HR and talent experience, Erin has broad and diverse expertise across talent management, talent acquisition, talent scouting, executive search, talent analytics and insights, and strategic leadership initiatives. She is also a certified leadership coach and a member of Chief, a network of women leaders.Erin is passionate about human connection, employee advocacy and engagement, and championing talent innovation. She thrives on leading high-performance teams across the globe to ensure the future success of the organization. Erin has a proven track record of delivering effective talent strategies in complex and innovative environments, as well as superior talent identification, engagement, business insights, competitive intelligence, and project management. She is an inclusive and servant leader who loves collaboration and partnership.SUE SAYS"I sit down with Erin Krolikiewicz of Novartis Pharmaceuticals to talk about being the first in her family to go to college, what it was like being an introvert and an old soul growing up, and how her divorce was one of the greatest challenges of her life."Support this podcast at — https://redcircle.com/women-to-watch-r/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

This 45-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology and treatment of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/Contact: CEServices@academycme.orgCopyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This 15-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system-pathophysiology/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/Contact: CEServices@academycme.orgCopyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This 30-minute CME-accredited program highlights the connection between the complement system and myasthenia gravis in regards to the treatment of this rare disease. Jointly Provided by American Academy of CME and CheckRare CE. Support for this accredited continuing education activity has been made possible through educational grant from UCB. Start date: December 18, 2023. End date: December 18, 2024 To receive CME credit, go to https://checkrare.com/learning/p-myasthenia-gravis-and-the-complement-system-treatment-options/ Activity FacultyJames F Howard Jr, MDProfessor of Neurology, Medicine & Allied Health Department of NeurologyThe University of North Carolina at Chapel HillTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology who may be involved in the diagnosis and care for individuals with TIO. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe efficacy of the treatment options for MG that target the complement system.Compare the safety of the treatment options for MG that target the complement system.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty EducatorDr. Howard discloses the following relevant financial relationships with ineligible companies:Grant/Research support (paid to his institution): Alexion Pharmaceuticals, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Myasthenia Gravis Foundation of America, Muscular Dystrophy Association, National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), Patient-Centered Outcomes Research Institute, and Ra Pharmaceuticals (now UCB Biosciences).Advisory Board/Consultant: Alexion Pharmaceuticals, argenx, Biologix Pharma, F. Hoffman-LaRoche Ltd, Immunovant Inc., Merck EMD Serono, NMD Pharma, Novartis Pharmaceuticals, Ra Pharmaceuticals (now UCB Biosciences), Regeneron Pharmaceuticals, Sanofi US, Horizon Therapeutics (now Amgen) Toleranzia AB, and Zai Labs. Shareholder (as part of a family trust): Johnson & Johnson, Pfizer, General Electric, GE Healthcare, GlaxoSmithKline, ViatrisNon-financial Support (meeting travel): Alexion Pharmaceuticals, argenx, Ra Pharmaceuticals (now UCB Biosciences), Toleranzia AB.Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.org Copyright© 2023. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

"Differential Diagnosis of Inflammatory Back Pain" Featuring: Drs. Ethan Craig and Lianne Gensler Sponsored by Novartis Pharmaceuticals Corporation

Anthony has been working in healthcare for more than 25 years. His professional career started in the 90s at the National Institutes of Health (NIH) doing bioinformatics for the Human Genome Project. He later shifted into Research and Development at Novartis Pharmaceuticals, where he was interested in contributing more directly to the development of new disease therapies. Although Anthony worked in healthcare, he was extremely sick! At 33 years old, he was denied a 20-year term life insurance policy. He was morbidly obese, weighing more than 360 pounds, medicated for high blood pressure, and suffering from psoriasis, eczema, migraine headaches, and sleep apnea. Through the transition to a whole food plant-based diet and healthy lifestyle, Anthony lost 160 lbs. and reversed all of these conditions. He has maintained that weight loss, optimal health, and a greatly improved quality of life for more than 15 years and counting. Driven to help others not experience the sickness he had to endure, Anthony realized that top-tier physicians were not available to the general public, either because of cost or availability (they lived in other states). Anthony decided to do something about it, by launching Love.Life Telehealth, an integrated health and wellness company, provides patient-centric medical care that's outcome-driven, personalized, and dedicated to addressing whole-body health. With licensed physicians practicing telehealth nationwide, Love.Life empowers patients to proactively improve their health by focusing on the root causes of chronic diseases and offering comprehensive solutions. Love.Life is a national network of wellness hubs that is leading the convergence of food, medicine, and wellness for a one-stop transformative health experience. In this podcast, we get into: ✅ How Anthony lost 160lbs on a plant-based diet ✅ Why the first time he attempted to lose 50lbs failed miserably ✅ Why he believes personalized Telemedicine is going to revolutionize healthcare ✅ How to start new habits and make them sticky & consistent

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Howard Berman, CEO and Chairman of the Board at Coya Therapeutics Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Howard, covering: How a neurology appointment with his father led to the creation of a biotech company focused on neurodegenerative, autoimmune, and metabolic diseases Having the DNA of an entrepreneur but taking the time to gain a big pharma foundation The harsh realities and characteristics required to start, fund, and grow a clinical-stage biotechnology company The need as a biotech CEO to be bullish, have confidence in your partners and be passionate about your disease... while celebrating the little successes Howard co-founded Nicoya Health in 2020 to realize the vision and research of Dr. Stanley Appel. He merged the company with Coya Therapeutics in 2021, where he currently serves as Chairman and CEO He has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify, and bridge both disciplines. Howard gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie. He spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and later Eli Lilly where he was the scientific point of contact between the company and key opinion leaders for the development and initiation of collaborations, clinical trials and investigator-initiated trials. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

Want to become more heart-centered? There's a new playbook in town! Deb is releasing her first book The Heart-Centered Leadership Playbook: How to Master the Art of Heart in Life & Leadership in September! Details at www.debcrowe.comWe're delighted to welcome back a distinguished guest, Glenn Parker, whose invaluable insights on leadership and teamwork were shared in our memorable Episode 165. Today, we're thrilled to spotlight Glenn's latest endeavor: the launch of his new book, “Positive Influence: Leadership in a Time of Crisis.” Drawing from his extensive experience and profound understanding, Glenn navigates the complexities of leadership during challenging times, offering a beacon of guidance for all aspiring leaders.And here's an exciting treat for our listeners - Glenn is extending an exclusive opportunity. The first five individuals to purchase his new book for someone else will receive a complimentary copy for themselves! To seize this chance, simply reach out to Glenn at glenn@thepositiveinfluenceleader.com with the recipient's mailing address. It's a wonderful way to dive into the wisdom of 'Positive Influence' and share its transformative power with others.Join us in embracing the positive influence of leadership with Glenn Parker, and let's embark on a journey of growth and resilience together.Glenn Parker is an internationally recognized workshop facilitator, organizational consultant, and conference speaker in the area of teamwork, collaboration, and team meetings. He is the author of sixteen books, including the bestsellers Cross-Functional Teams: Working with Allies, Enemies and other Strangers, and Team Players and Teamwork: New Strategies for Developing Successful Collaboration. Glenn's widely-used instrument, the Parker Team Player Survey, has sold more than one million copies, and his seminal work on team player styles was featured in a bestselling CRM video.Glenn and his son, Michael are co-authors of Positive Influence: The Leader Who Helps People Become Their Best Self (HRD Press, 2020) and just released, Positive Influence: Leadership in a Time of Crisis (HRD Press, 2023).As a consultant for more than forty years, Glenn Parker has helped create high-performing teams at hundreds of organizations including Novartis Pharmaceuticals, Merck & Company, Bristol-Myers Squibb, Phillips-Van Heusen, Telcordia Technologies, BOC Gases, and the U.S. Coast Guard. Glenn holds a Master's degree from the University of Illinois, and studied for the doctorate at Cornell University. Through his philanthropic endeavors, he has raised over $1.5 million for cancer research.Connect with Glenn at:* https://www.linkedin.com/in/glennparker/* http://www.thepositiveinfluenceleader.com/* https://twitter.com/teamguy518* https://www.facebook.com/Team36SkillBoy This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit debcrowe.substack.com

Welcome to the latest episode of Endpoints Shorts, presented by the ALS Therapy Development Institute. I'm Jonathan Gang. In these bite-size podcasts, we'll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space ­– all in 15 minutes or less. Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI's Director of Community Outreach and Engagement. Today, Nadia joins us to talk about Novartis Pharmaceuticals' phase 2 trial for BLZ945.Support the show: https://www.als.net/donate/See omnystudio.com/listener for privacy information.

Rip welcomes Anthony Masiello, co-founder and CEO of Love Life Telehealth, who shares his personal transformation and innovative approach to healthcare access to whole food plant-based physicians. Anthony recalls his own struggle with weight issues from a young age, trying various methods to lose weight. Despite his active lifestyle, his weight continued to fluctuate, leading him to question how weight gain occurs and the role of genetics and environment in this process. After sharing his own personal journey, Anthony delves into the creation of Love Life Telehealth, a platform that aims to revolutionize healthcare by providing comprehensive support through coaching, education, and community. He explains the concept of telemedicine and how Love Life Telehealth connects patients with doctors across different states, offering lifestyle medicine consultations. The ultimate goal of Love Life Telehealth is to change the way healthcare is practiced, prioritizing a lifestyle-first approach and using medicine only when necessary. The team of ten doctors work collaboratively with patients to understand their complete profile and help them achieve their goals. Anthony describes the development of other programs and offerings, such as a monthly payment model and a year-long program, all designed to help people not just live life, but love life and be passionate about enjoying it. About Anthony Masiello Anthony has been working in healthcare for more than 25 years. His professional career started in the 90s at the National Institutes of Health (NIH) doing bioinformatics for the Human Genome Project. He later shifted into Research and Development at Novartis Pharmaceuticals, where he was interested in contributing more directly to the development of new disease therapies. After transforming his own health, and learning there is a better way, he shifted once again and is now 100% focused on providing access to medical services centered on the prevention and reversal of disease utilizing lifestyle medicine rooted in whole food plant-based nutrition. Anthony came to a plant-based lifestyle himself after being denied a 20-year term life insurance policy at age 33. He was morbidly obese, weighing more than 360 pounds, medicated for high blood pressure, and suffering from psoriasis, eczema, migraine headaches, and sleep apnea. Through the transition to a whole food plant-based diet and healthy lifestyle, Anthony lost 160 lbs. and reversed all of these conditions. He has maintained that weight loss, optimal health, and a greatly improved quality of life for more than 15 years and counting. Anthony's personal health transformation has been featured on the Megyn Kelly Today show, on PBS, in The Huffington Post, in the bestselling book Eat to Live, and by Forks Over Knives, Runners World, and numerous magazines, websites, radio shows, podcasts, and articles. Anthony was Co-founder and CEO of Plant Based TeleHealth, a national lifestyle telemedicine service focused on the prevention and reversal of disease with lifestyle medicine and whole food plant-based nutrition. In 2022, Plant-Based TeleHealth was acquired by Love.Life, a national network of wellness hubs that is leading the convergence of food, medicine, and wellness for a one-stop transformative health experience.   Episode Resources Watch the Episode on YouTube Love.Life Telehealth Join our PLANTSTRONG Sedona Retreat - October 9-14, 2023 To stock up on the best-tasting, most convenient, 100% PLANTSTRONG foods, including our cornbread, teas, stews, pancakes cereals, granolas, pizza kits, broths and soups, check out all of our PLANTSTRONG products HERE. Give us a like on the PLANTSTRONG Facebook Page and check out what being PLANSTRONG is all about. We always keep it stocked full of new content and updates, tips for healthy living, delicious recipes, and you can even catch me LIVE on there! We've also got an Instagram! Check us out and share your favorite PLANTSTRONG products and why you love it! Don't forget to tag us using #goplantstrong

David Epstein joined Seagen as Chief Executive Officer and a member of the Board of Directors in 2022, bringing more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale. Prior to Seagen, he was executive partner at Flagship Pioneering. From 2010 to mid-2016 he served as Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG.Previously, David started and led Novartis' Oncology and Molecular Diagnostic units. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto.David holds a B.S. Degree in Pharmacy from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business. He serves as a member of the board of directors for OPY Acquisition Corp. I and Senti Biosciences, Inc.w/ Special Guest Host: Brian Fiske - Co-Founder & CSO @ Mythic TherapeuticsBrian Fiske co-founded Mythic in 2017 & currently serves as Mythic's Chief Scientific Officer. Prior to Mythic, he was a co-founder and Chief Technology Officer at Ohana Biosciences and a Senior Associate at Flagship Ventures, where he also co-founded KSQ Therapeutics. During his time at Flagship, Brian successfully led R&D teams to key milestones, recruited 25+ FTEs across all levels of seniority, and raised $34M across multiple rounds of financing. In 2016, he was nationally recognized for healthcare entrepreneurship by Forbes 30 under 30.Prior to Flagship, Brian completed his PhD in biology in Matt Vander Heiden's lab at MIT where he published over 10 papers in the field of cancer metabolism. He also worked closely with Agios Pharmaceuticals (NASDAQ: AGIO) on their cancer metabolism programs, which have since translated into four clinical programs that include two approved drugs. He holds an AB summa cum laude in Biochemical Sciences with a secondary field in Economics from Harvard University.Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

How can people managers truly become allies and support their teams? How can they create psychologically safe environments that promote creativity and curiosity? On Part 2 of our interaction with James Brook, we dive deep into people managers turning mentors, pushing team members while creating safe environments and leading them towards constant progressive paths. Note: Mr James Brook, is an entrepreneur, business psychologist, and leadership coach based in the UK with 3 decades of experience in assessment, talent and leadership development and coaching. He created the next generation of talent assessment tool, TalentPredix™ to help employers hire talented people and empower them to thrive at work. In the past, James has pioneered the strengths-based approach to talent management in the UK, founding Strengthscope® in 2006 and has worked with clients including LVMH, Tesco, Novartis Pharmaceuticals, Oracle and Facebook among others. He has also authored multiple books on organizational management and leadership including, Strengths for Success – Your Pathway to Peak Performance, Optimize Your Strengths, and Stretch: Leading Beyond Boundaries. P.S- Also listen to Part 1 of the episode wherein James decodes nurturing and building strengths while also stretching strengths of team members. Original music by Joseph Mc Dade   Drop us a note on Instagram, Facebook, LinkedIn or Twitter @voice_of_achievers Or write in directly to editor@voiceofachievers.com We're listening to you. Don't forget to follow us on Spotify, Stitcher, Apple, Google, JioSaavn, Gaana or wherever you're listening to us! You can follow us and leave us feedback on Facebook, Instagram, and Twitter @eplogmedia, For partnerships/queries send you can send us an email at bonjour@eplog.media.   DISCLAIMER: The views expressed on all the shows produced and distributed by Ep.Log Media are personal to the host and the guest of the shows respectively and with no intention to harm the sentiments of any individual/organization.The said content is not obscene or blasphemous or defamatory of any event and/or person deceased or alive or in contempt of court or breach of contract or breach of privilege, or in violation of any provisions of the statute, nor hurt the sentiments of any religious groups/ person/government/non-government authorities and/or breach or be against any declared public policy of any nation or state.See omnystudio.com/listener for privacy information.

How should leaders deal with mistakes? How can strengths psychology be used to power teams? We decode aspects of strengths psychology for achieving peak performance, embracing vulnerability, dealing with mistakes, building and nurturing trust and more on this special episode from our mini People and HR series. Our guest Mr James Brook, an entrepreneur, business psychologist and leadership coach based in the UK with 3 decades of experience in assessment, talent and leadership development and coaching. He created the next generation of talent assessment tool, TalentPredix™ to help employers hire talented people and empower them to thrive at work. In the past, James has pioneered the strengths-based approach to talent management in the UK, founding Strengthscope® in 2006 and has worked with clients including LVMH, Tesco, Novartis Pharmaceuticals, Oracle and Facebook among others. He has also authored multiple books on organizational management and leadership including, Strengths for Success – Your Pathway to Peak Performance, Optimize Your Strengths, and Stretch: Leading Beyond Boundaries.   Hear him talk about: (02.00) - Nurturing strengths; strengths spotting, finding what's energizing and challenging (03.15) - The observation and inference fallacy- ask vs observe while making judgments (04.30) - stretching your strengths & performance dialogues about challenging aspects @work (06.00) - Why it's important to pay attention to high performing team members & A players (07.30) - How should leaders address mistakes- transparency & acknowledging vulnerability (09.30) - Dealing with hybrid and remote work culture as people managers (11.00) - Creating a welcoming environment to retain talent- - relevance of strengths, inclusion, cognitive diversity (13.30) - Building and nurturing an environment of trust (14.30) – The pygmalion effect & trust (15.45) - Setting clear expectations as leaders & people managers (17.00) - The business process & people management/ emotional management dichotomy of HR (19.00) - The relevance of investing in talent as people managers (20.30) - HR becoming strategic partners; building courage to question (22.00) - Optimizing talents and strengths Original music by Joseph Mc Dade   Drop us a note on Instagram, Facebook, LinkedIn or Twitter @voice_of_achievers Or write in directly to editor@voiceofachievers.com We're listening to you. Don't forget to follow us on Spotify, Stitcher, Apple, Google, JioSaavn, Gaana or wherever you're listening to us! You can follow us and leave us feedback on Facebook, Instagram, and Twitter @eplogmedia, For partnerships/queries send you can send us an email at bonjour@eplog.media.   DISCLAIMER: The views expressed on all the shows produced and distributed by Ep.Log Media are personal to the host and the guest of the shows respectively and with no intention to harm the sentiments of any individual/organization.The said content is not obscene or blasphemous or defamatory of any event and/or person deceased or alive or in contempt of court or breach of contract or breach of privilege, or in violation of any provisions of the statute, nor hurt the sentiments of any religious groups/ person/government/non-government authorities and/or breach or be against any declared public policy of any nation or state.See omnystudio.com/listener for privacy information.

Novartis Pharmaceuticals Corporation v. Carole Johnson

This episode kicks off a series of special podcasts for KGI's 25th anniversary. In this episode, we hear from KGI Board of Trustee members Dr. Ross Grossman, Teresia Bost, and Dr. Lydia Villa-Komaroff on the future of biotech and the life sciences. The discussion was recorded on October 7, 2022, during KGI's Founder's Day celebration. Grossman served as the Chief Human Resources Officer at Regeneron Pharmaceuticals from 2002 until his retirement in 2013, later returning to that role in April 2015 until his second retirement in May 2016. He previously held senior Human Resources roles at Novartis Pharmaceuticals, Prudential Financial, and UBS. Bost serves as General Counsel at health technology company 54gene, overseeing legal, compliance, and cybersecurity functions. 54gene advances the state of healthcare through large-scale discovery and translational research, advanced molecular diagnostics, and clinical programs for the benefit of Africans and the global population. Villa-Komaroff is a molecular biologist, an executive, and a diversity advocate, in addition to being founder and principal of Intersections SBD Consulting. She is also the Chair of the KGI School of Community Medicine Board of Governors. The three panelists are joined by moderator Bonnie Anderson, CoFounder and Executive Chair of Veracyte. Bonnie is also a KGI Trustee Emeritus and Most Influential Honoree.

Welcome to another episode of The Action and Ambition Podcast! Joining us today is Pandit Dasa, a former monk, mindfulness expert, author, and international keynote speaker who speaks to Fortune 100 and Fortune 500 companies. He emphasizes self-care, the origin of all success. Some of the organizations he has spoken to are Google, NASA, London Stock Exchange, IBM, Citibank, World Government Summit, Kellogg, Cadillac, Federal Reserve Bank of Chicago, Nationwide Insurance, Novartis Pharmaceuticals, Pfizer, JPMorgan Chase, Bank of America and many others. Don't miss a thing on this. Tune in to learn more!

Anthony was morbidly obese, weighing more than 360 pounds,  Anthony was medicated for high blood pressure, and suffering from psoriasis, eczema, migraine headaches, and sleep apnea. Watch Interview See Before and After Pictures! Through the transition to a whole food plant-based diet and healthy lifestyle, Anthony lost 160 lbs. and reversed all of these conditions. He has maintained that weight loss, optimal health, and a greatly improved quality of life for more than 15 years and counting.

In this episode, Damali discusses the experience of working as a health care physician during the COVID 19 pandemic with Dr. Melanie Shorter-Jones. She is a family medicine physician, and has been serving the middle Georgia area for over 15 years. She has served as a physician speaker for Pfizer Pharmaceuticals and Novartis Pharmaceuticals. Additionally, she has been a clinical preceptor for the Mercer School of Medicine, Morehouse School of Medicine, and the Philadelphia College of Medicine. She is a graduate of Albany State University (undergrad) and the University of Tennessee College of Medicine. Her residency training was completed at the Tallahassee Memorial Family Medicine Program. Dr. Melanie Shorter Jones shares that her resilience comes from her female role models in life. She gives advice on how to speak up and to seek opportunities.

Glenn Parker is an internationally recognized workshop facilitator, organizational consultant, and conference speaker in the area of teamwork, collaboration, and team meetings. He is the author of sixteen books, including the bestsellers Cross Functional Teams: Working with Allies, Enemies and other Strangers, and Team Players and Teamwork: New Strategies for Developing Successful Collaboration. Glenn's widely-used instrument, the Parker Team Player Survey, has sold more than one million copies, and his seminal work on team-player styles was featured in a bestselling CRM video. As a consultant for more than forty years, Glenn Parker has helped create high-performing teams at hundreds of organizations including Novartis Pharmaceuticals, Merck & Company, Bristol-Myers Squibb, Phillips-Van Heusen, Telcordia Technologies, BOC Gases, and the U.S. Coast Guard. Glenn holds a Master's degree from the University of Illinois, and studied for the doctorate at Cornell University. Through his philanthropic endeavors, he has raised over $1.5 million for cancer research. Some of the topics covered in this episode: 1. The research completed to write the book/the creative process • In-depth interviews with some 50 people with diverse backgrounds – jobs, industries, gender, ethnicity, born outside us 2. The 4 types of positive influence leaders • Supportive • Teacher • Motivating • Role model 3. How can you tell what kind of leader you are? 4. Most of us have come across negative people in our lives --- how do people cope with negativity they encounter? 5 coping strategies for dealing with negativity: 1) Take it on as a challenge 2) Take responsibility for the situation 3) Persevere in the face of adversity 4) Adopt a calm and reasoned approach 5) Use the negativity as a learning experience 5. How positive influence leaders lead in a time of crisis 1. Be open and authentic 2. Be clear and specific 3. Listen, ask questions, listen some more and respond 4. Walk the talk 5. Conduct an after-action review • What did we do? • What went well • What didn't • What would we do differently next time? • What did we learn? • What did we do that we will want to incorporate in the going forward workplace? • We don't just want to do back to a new normal but to a better normal! 6. Here's the “so what” question? Let's assume I am the CEO of a company or a non-profit corporation, how do I use all this to increase the effectiveness of my organization? Glenn's Special Offer detailed near the end of the episode will require this: glenn@thepositiveinfluenceleader.com To purchase their book, learn more about, or to connect with Glenn and his son Michael, visit: https://thepositiveinfluenceleader.com/ https://www.linkedin.com/in/glennparker/ https://twitter.com/teamguy1

In this episode of Women @ RopesTalk, hosted by health care partner Christine Moundas, life sciences partner and Women's Forum co-chair Katherine Wang interviews Ingrid Zhang, president of Novartis Pharmaceuticals China. Ingrid talks about her early interest in health care and why she decided to go to business school. As she reflects on her career path, from consulting to working in the pharmaceutical industry, Ingrid shares her advice for early career professionals, especially why developing a thick skin is so important for growth. She also describes the exciting regulatory changes in China's health care market, as well as unique aspects of Novartis's culture.

Today, I am joined by Anthony Masiello, co-founder and CEO of Plant Based TeleHealth, a national lifestyle telemedicine service focused on the prevention and reversal of disease with lifestyle medicine and whole food plant-based nutrition. Anthony has been working in healthcare for more than 25 years. His professional career started in the 90s at the National Institutes of Health (NIH) doing bioinformatics for the Human Genome Project. He later shifted into Research and Development at Novartis Pharmaceuticals, where he was interested in contributing more directly to the development of new disease therapies. Finally, after learning there is a better way, he shifted his focus once again and is now 100% focused on providing access to medical services centered on the prevention and reversal of disease utilizing lifestyle medicine rooted in whole food plant-based nutrition. Anthony first came to a plant-based lifestyle himself after being denied a 20-year term life insurance policy at age 33. He was morbidly obese, weighing more than 360 pounds, medicated for high blood pressure, and suffering from psoriasis, eczema, migraine headaches, and sleep apnea. Through the transition to a whole food plant-based diet and healthy lifestyle, Anthony lost 160 lbs. and reversed all of these conditions. He has maintained that weight loss, optimal health, and a greatly improved quality of life for more than 15 years and counting. Anthony's personal health transformation has been featured on the Megyn Kelly Today show, on PBS, in The Huffington Post, in the bestselling book Eat to Live, and by Forks Over Knives, Runners World, and numerous magazines, web sites, radio shows, podcasts, and articles. Visit his website: https://plantbasedtelehealth.com/ Follow Anthony: Instagram: @amasiello https://instagram.com/amasiello/ @plantbasedtelehealth https://instagram.com/plantbasedtelehealth Facebook: https://www.facebook.com/anthonymasiello https://www.facebook.com/PBTeleHealth and YouTube: https://www.youtube.com/c/PlantBasedTeleHealth Be sure to subscribe to the podcast and if you're loving it, please give Did You Bring the Hummus a 5 star rating, it's an easy way to keep supporting the show. Are you a change-maker? Do deeply care about changing the systems which oppress others and is it important to you to reduce suffering and to find powerful, consistent ways to do that? My new course, The Vegan Voyage, launching October 19th, is just what you're looking for. Visit my website for more details. https://www.didyoubringthehummus.com/veganvoyage Theme song: ©2020 JP Winters © 2021 Kimberly Winters - Did You Bring the Hummus LLC

Welcome to The Profit Talk! In this show, we're going to help you explore strategies to help you maximize profits in your business while scaling and creating the lifestyle that you want as an entrepreneur. I am your host, Susanne Mariga! I'm a certified Mastery Level Profit First Professional. Let's dive into strategies to maximize profits in your business! In this episode I interview, CEO Development Strategist, Kelly Ruta. Kelly has a Bachelor's degree in Psychology, a Master's Degree in Social Work, and a postgraduate certificate in Substance Abuse Counseling, all with Honors. She's worked with the Women's Leadership Initiatives at McDonald's and Novartis Pharmaceuticals, in addition to, well-known online businesses such as Screw The Nine to Five, EPIC At Sales, and Heart Behind Hustle. She is the Mindset Expert Faculty member for Profit First Professionals and speaks from LIVE and virtual stages to inspire audiences and compel CEOs to develop themselves as strategically as they do their business initiatives. To learn more about Kelly and the services she provides, go to www.kellyruta.com Visit my FREE Facebook Group, The Profit First Masterclass, where I'll be sharing additional exclusive trainings to members of the community.  If you're excited about what's next for your business and upcoming episodes, please head to our itunes page and give us a review! Your support will help me to bring in other amazing expert interviews to share their best tips on how to powerfully grow in your business! DISCLAIMER: The information contained within these videos is provided for informational purposes only and does not constitute, an accountant-client relationship. While we use reasonable efforts to furnish accurate and up-to-date information, we assume no liability or responsibility for any errors, omissions, or regulatory updates in the content of this video. Any U.S. federal tax advice contained within is not intended to be used for the purpose of avoiding penalties under U.S. federal tax law.

Navigating the Complexities of Health Literacy and MS - Episode 38 - Transcript This episode is brought to you by our sponsors Biogen, Genentech, and Novartis Pharmaceuticals. Today we're featuring Psychologist Roz Kalb, Neurologist Lilyana Amezcua, and Shawn Feliciano. We'll discuss how ethnicity and health literacy has shaped Shawn's MS journey and what self-advocacy tools she employs to live her best life. We'll also hear from Lilyana about what makes MS in the Hispanic and Latino communities unique, and the research being conducted to better understand MS in this space.

While estimates vary, spending on prescription drugs in the United States exceeds $500 billion per year. This makes drug prices a perennial health policy topic.In this context, payers and manufacturers are in a constant battle. Manufacturers seek to expand their market while payers attempt to use their leverage to negotiate lower drug prices. Often, patients and clinicians are caught in the middle and left to navigate increasingly complex pharmaceutical insurance benefit design, tiered formularies, drug rebates, and drug coupon programs.On today's A Health Podyssey, Scott Howell, chief strategy officer of US pharmaceuticals at Novartis Pharmaceuticals, joins Health Affairs Editor-in-Chief Alan Weil to discuss how much the United States health system spends on drug utilization management.Howell and co-authors published a paper in the August 2021 issue of Health Affairs exploring the growing burden of drug utilization management and seeking to quantify its financial cost. They found combined costs shared among payers, manufacturers, physicians, and patients totaling almost a hundred billion dollars per year.Order the August 2021 issue.Subscribe: RSS | Apple Podcasts | Spotify | Stitcher | Google Podcasts

Dr. Mark Hinkes is a Doctor of Podiatric Medicine who recently retired from clinical care after 40 years' service. 20 years in private practice in Miami, FL and 20 years at the Veterans Affairs Medical Centers. In Nashville, Tennessee he served as the Chief of Podiatry Services and Director of Podiatric Medical Education. He has been the Chairman of the Preservation Amputation Care and Treatment (PACT) Program for over a decade.His service was responsible for providing the full spectrum of foot health care including primary podiatric medicine, pedal biomechanical evaluations, orthotic/prosthetic services, preventive foot care for patients with diabetes and at-risk limbs, wound care and foot surgery. He also provided consultation services for primary care, emergency care services, and specialty service clinics.Before moving to Nashville, Dr. Hinkes was the Chief of the Podiatry Service at the Veterans Affairs Medical Center in Salem, Virginia. He served as National Field Advisor for Quality Assurance for Podiatric Medicine for the Veterans Administration. Dr. Hinkes has been a consultant for hospitals, extended care facilities, and corporations. He has served on multiple hospital committees, lectured nationally and internationally for community groups and schools, and has published peer-reviewed journal articles. He is the author of two books on diabetic foot health, Keep The Legs You Stand On, and Healthy Feet for People with Diabetes. Dr. Hinkes participated in teaching podiatric medicine at the graduate level at Barry University School of Podiatric Medicine in Miami, Florida from 1987 to 1998 as Adjunct Associate Professor of Podiatric Medicine. He is bilingual, English-Spanish, and has been a consultant to the electronic and print media in both languages. He has been President of the Dade County (Florida) Podiatric Medical Association. He has served as a clinical investigator for Novartis Pharmaceuticals.Dr. Hinkes started his podiatric medical career in Miami, Florida where he completed his American Podiatric Medical Association-approved medical/surgical residency training at Westchester General Hospital. Dr. Hinkes graduated in May 1976 from Ohio College of Podiatric Medicine in Cleveland, Ohio as a member of Phi Alpha Pi Professional Fraternity. In January 1973, he obtained his Bachelor of Science in Psychology from Loyola University of Chicago, Illinois. His teaching at post-graduate level included Vanderbilt University School of Nursing and Geriatric Medicine in Nashville that focused on common foot problems with an emphasis on the diabetic foot, ulcer and amputation prevention in the at-risk patient.Dr. Hinkes is certified by the American Board of Foot and Ankle Surgery and the American Professional Wound Care Association. He is a diplomat of the American College of Foot & Ankle Surgeons. His professional memberships include the American Podiatric Medical Association, American Podiatric Writers Association, American Professional Wound Care Association and Association for the Advancement of Wound Care. He is a frequent blog contributor to several wound care blogs including Podiatry Today Magazine and his personal LinkedIn site. He is President and CMO of ePrevenir, a company who offers a cloud-based tool for Primary Care Providers to manage the four comorbidities of diabetes. In his leisure time, Dr. Hinkes enjoys raising roses, traveling, playing backgammon, and creating stained glass art.Follow Knowledgeable Aging:Facebook: https://www.facebook.com/Knowledgeable-Aging-102638398162823Twitter: https://twitter.com/KnowledgeAgingInstagram: https://www.instagram.com/knowledgeableaging/LinkedIn: https://www.linkedin.com/company/knowledgeable-aging/?viewAsMember=trueSpotify: https://open.spotify.com/show/05OHF9FkmhzCO5PDsyGfGqNewsletter: https://www.knowledgeableaging.com/newsletter/

In unserer Nachmittagsfolge tauchen wir heute ein in die spannende Welt der MetTechs. Als ersten Gast begrüßen wir heute Stefan Zundel, Co-Founder und Managing Director von Dopavision. Dopavision entwickelt ein digitales Therapeutikums, um Kurzsichtigkeit (Myopie) bei Kindern und Jugendlichen zu heilen. Hamed Bahmani und Stefan Zundel gründeten 2017 das Startup mit Hauptsitz in Berlin. Das Startup aus dem Company Builder Flying Health hat nun eine Series-A-Finanzierungsrunde in Höhe von 12 Millionen Euro eingesammelt. Seventure Partners, Novartis Pharmaceuticals und Altinvestoren wie Boehringer Ingelheim Venture investiertrten in das Medizintechnik-Startup. Das frische Kapital soll unter anderem in die “Weiterentwicklung der digitalen Therapie” fließen Im zweiten Interview berichtet Dr. Achim Plum, CEO von InfanDx, über die Erstrundenfinanzierungs des Diagnostik-Unternehmens. InfanDx konzentriert sich auf die Entwicklung und Vermarktung von diagnostischen Lösungen für Neugeborene. Das Leitprodukt in der klinischer Entwicklung ist der InfanDx HypoxE-Test®, der auf die zuverlässige Diagnose von hypoxisch-ischemische Enzephalopathie (HIE) innerhalb der ersten Stunden nach der Geburt abzielt. Anlass für das Gespräch ist die 4 Millionen Euro umfassende Serie A-Finanzierung. Die Erstrunde wurde durch die Alluti GmbH - Smart Invest – das Family Office des Markenexperten Bert Bleicher sowie den Altinvestoren Jochen Tschunke und LSI Pre-Seed Fonds GmbH des Life Science Inkubator Bonn unterstützt. Außerdem begrüßen wir erneut Mathias Ockenfels, General Partner bei Speedinvest, der uns den heute announcten Spezialfonds in Höhe von 60 Mio. Euro von Speedinvest vorstellt. Der Paneuropäische Speedinvest x Fund 2 fokussiert sich auf Marketplaces- und Consumer-Start-ups und wird neben Styria Digital Marketplaces und Russmedia Equity Partners von rund einem Dutzend Marketplaces-Unternehmern und - Führungskräften unterstützt, unter anderem Jörg Gerbig, COO von JustEatTakeAway, und die Gründer von Ankorstore und Vinted.

Novartis Pharmaceuticals v. Accord Healthcare Inc.

Motivational Leadership was co-founded by our guest Kate Turner over 20 years ago to "shift the paradigm of motivation and leadership in the workplace"  She and her associates strongly believe that motivation is an essential ingredient of performance, yet isn't well understood, or indeed nurtured, by organisations. And yet It drives employee engagement and enables cultural change.With her co-founder and other team members, Kate delivers leadership solutions using Motivational Maps to clients such as Novartis Pharmaceuticals, John Lewis Partnership, Alzheimer's Society and the UK's leading animal charity RSPCA.In April 2020, just after the UK's first national Covid-19 lockdown,  Kate's book CREATE Motivation was launched. Whilst written and published before the pandemic, she could not have known how prescient and impactful its content would be. The book has become an Amazon best-seller and in this interview we ask Kate what her motivation was to write it.  In the Free Resources section below, Kate shares with you the companion guide to the book which illustrates more fully the 'What/How/Why Bother' model which we refer to throughout our interview. As usual many analogies with sheep, shepherding and dogs are discussed. One somewhat surprising reference is made to how both our sheep-herding exercise and the pandemic are both levellers - everyone needs to be agile and flexible in their response and to value the support and collaboration of the team around us.  And both situations require knowledge of people's motivation to take action - why bother? - to use Kate's expression.If this episode has prompted any questions, please go ahead and ask - either email caroline@raisingthebaa.com or leave it in your review!Enjoy - and thank ewe for listening :-)Free resources:Free companion guide to Kate's best-selling book CREATE MotivationFree e-book authored by Kate - Motivation During a Global PandemicSheep, Shepherd or Dog - which one are ewe? Take our personality quiz and find out.Connect with the speakers via LinkedIn:Caroline Palmer - Top Dog and Co-Founder, Raising the BaaChris Farnsworth - Head Shepherd and Co-Founder, Raising the BaaKate Turner - Founding Director, Motivational Leadership and published author of CREATE Motivation

runtime: 60 mins / CTA, Malaysia, Grand Slams, college tennis, grassrootsHow's it going everyone! This was a fun recording with Alfie Cheng, the middle brother of three Cheng brothers from Kangar, Perlis, Malaysia. This is a tennis family make no mistake, older brother went to Furman in South Carolina, and the youngest brother, Alvin, went to Eastern Kentucky University, a couple of years after Alfie. The dude works for Novartis Pharmaceuticals and lives with his family in Somerset, Kentucky. 

Vas NarasimhanCEO, Novartis Pharmaceuticals"I think that the guilt [from more distributed work] comes from a good place for most people, which is this passion to want to do a good job, feeling a deep commitment to the mission of our company, and then really wanting to show that through activity. But, it's really about impact. It's not about activity."Vas Narasimhan's third year as CEO of Novartis was unlike any other. Grounded from travel, he sought to continue his pursuit of Novartis' mission to reimagine medicine... from his son's bedroom.Vas' refreshing transparency and optimism are on full display in this wide-ranging conversation on the future of work. He and Scott Peltin discuss topics such as:_the successes and failures of his personal evolution into distributed work_a hypothetical model for hybrid work_his new morning routine_reframing the guilt we sometimes feel when working in a results-only environment_ a more strategic, discerning approach to future travel_how he satisfies his curiosity in the absence of face to face interactionsHis energy and perspective present a template for any leader seeking to multiply the energy of the people they impact. We hope you enjoy it.

Dr. Mark Hinkes is a Doctor of Podiatric Medicine who recently retired from clinical care after 40 years’ service. 20 years in private practice in Miami, FL and 20 years at the Veterans Affairs Medical Centers. In Nashville, Tennessee he served as the Chief of Podiatry Services and Director of Podiatric Medical Education. He has been the Chairman of the Preservation Amputation Care and Treatment (PACT) Program for over a decade.His service was responsible for providing the full spectrum of foot health care including primary podiatric medicine, pedal biomechanical evaluations, orthotic/prosthetic services, preventive foot care for patients with diabetes and at-risk limbs, wound care and foot surgery. He also provided consultation services for primary care, emergency care services, and specialty service clinics.Before moving to Nashville, Dr. Hinkes was the Chief of the Podiatry Service at the Veterans Affairs Medical Center in Salem, Virginia. He served as National Field Advisor for Quality Assurance for Podiatric Medicine for the Veterans Administration. Dr. Hinkes has been a consultant for hospitals, extended care facilities, and corporations. He has served on multiple hospital committees, lectured nationally and internationally for community groups and schools, and has published peer-reviewed journal articles. He is the author of two books on diabetic foot health, Keep The Legs You Stand On, and Healthy Feet for People with Diabetes. Dr. Hinkes participated in teaching podiatric medicine at the graduate level at Barry University School of Podiatric Medicine in Miami, Florida from 1987 to 1998 as Adjunct Associate Professor of Podiatric Medicine. He is bilingual, English-Spanish, and has been a consultant to the electronic and print media in both languages. He has been President of the Dade County (Florida) Podiatric Medical Association. He has served as a clinical investigator for Novartis Pharmaceuticals.Dr. Hinkes started his podiatric medical career in Miami, Florida where he completed his American Podiatric Medical Association-approved medical/surgical residency training at Westchester General Hospital. Dr. Hinkes graduated in May 1976 from Ohio College of Podiatric Medicine in Cleveland, Ohio as a member of Phi Alpha Pi Professional Fraternity. In January 1973, he obtained his Bachelor of Science in Psychology from Loyola University of Chicago, Illinois. His teaching at post-graduate level included Vanderbilt University School of Nursing and Geriatric Medicine in Nashville that focused on common foot problems with an emphasis on the diabetic foot, ulcer and amputation prevention in the at-risk patient.Dr. Hinkes is certified by the American Board of Foot and Ankle Surgery and the American Professional Wound Care Association. He is a diplomat of the American College of Foot & Ankle Surgeons. His professional memberships include the American Podiatric Medical Association, American Podiatric Writers Association, American Professional Wound Care Association and Association for the Advancement of Wound Care. He is a frequent blog contributor to several wound care blogs including Podiatry Today Magazine and his personal LinkedIn site. He is President and CMO of ePrevenir, a company who offers a cloud-based tool for Primary Care Providers to manage the four comorbidities of diabetes. In his leisure time, Dr. Hinkes enjoys raising roses, traveling, playing backgammon, and creating stained glass art.Follow Knowledgeable Aging:Facebook: https://www.facebook.com/Knowledgeable-Aging-102638398162823Twitter: https://twitter.com/KnowledgeAgingInstagram: https://www.instagram.com/knowledgeableaging/LinkedIn: https://www.linkedin.com/company/knowledgeable-aging/?viewAsMember=trueSpotify: https://open.spotify.com/show/05OHF9FkmhzCO5PDsyGfGqNewsletter: https://www.knowledgeableaging.com/newsletter/

Welcome to episode 19 of the Ben Morton Leadership Podcast and to my interview with Haseeb Ahmad. Haseeb is the Global Head of Value & Access and Commercial Development, and is Country President of Novartis UK, one of the world's leading Pharmaceutical Companies. In his role, he is a member of Novartis' global Pharmaceutical Executive Committee. Personal Leadership Mastery Check out my brand new online course, Personal Leadership Mastery, designed to help you and your team play at your best in the new normal, post-covid world. And remember to use you Friends of the Podcast discount code and save 30% on the regular tuition cost. Sign-up for the course https://benmortonleadership.thinkific.com/courses/personal-leadership-success-system (here) for just £139.00 with discount code 'FRIENDS21'. Episode Overview Haseeb is also President and Chairman of the Board at the Association of the British Pharmaceutical Industry, through which he is an active contributor to the UK Life Sciences' sector. He is also a board member of NHS England's Accelerated Access Collaborative. Haseeb has held numerous senior in-country appointments, including Managing Director of UK, Ireland and Nordics for Novartis Pharmaceuticals, Managing Director for MSD in Greece during the economic crisis, and global roles in Strategy, Operations, Sales and Marketing. In this episode Haseeb talks candidly about his ongoing leadership journey, how in the early part of his career he focused on lighting a fire under people's feet, and how he now focuses on lighting a fire in their hearts. Without any further delay, please enjoy my interview with Haseeb Ahmad. #LeadOn Links mentioned: https://benmortonleadership.thinkific.com/courses/personal-leadership-success-system (Personal Leadership Mastery by Ben Morton) https://www.amazon.com/Winning-Jack-Welch/dp/0060759380/ (‘Winning' by Jack Welch) https://www.amazon.com/Discover-Your-True-North-George/dp/1119082943/ref=sr_1_1?crid=2430VX5Z34D8G&dchild=1&keywords=true+north+bill+george&sprefix=true+north+bil%2Caps%2C275&sr=8-1 (‘True North' by Bill George) https://www.amazon.com/Leadership-Challenge-Extraordinary-Things-Organizations/dp/0470651725 (‘The Leadership Challenge' by Barry Posner and James Kouzes) https://www.amazon.com/Long-Walk-Freedom-Autobiography-Mandela/dp/0316548189/ (‘Long Walk To Freedom' by Nelson Mandela) https://www.amazon.com/Power-Now-Guide-Spiritual-Enlightenment/dp/1577314808/ (‘The Power of Now' by Ekhart Tolle) https://ouraring.com/ (Oura Ring)

Today on the Drop In CEO podcast, Dirk Horn shares how his experience with psychology and human resources led him to a deeper understanding of humans and how they are inspired to lead others. Listen in as Deborah and Dirk discuss how commitment changes outcomes, the power of having someone who believes in you, and the difference between authentic and functional relationships. Dirk is equipped with 17+ years of experience in Corporate Human Resources and several years as senior consultant and Executive Coach. He is an expert on transformation and organizational behavior and is passionate about good project management and successful implementation. Dirk holds a Master of Art in Social Sciences from the University of Goettingen, is a certified 360 Coach and HBDI® practitioner. He started his career with Norsk Hydro in 1997, moved to CLAAS Harvesting Machinery in 2002 and has since then gathered extensive experience in both Roche and Novartis Pharmaceuticals in Germany, Switzerland and the US. In 2013, Dirk decided to change the sides and continues to serve corporations as an external consultant. Since then he has successfully run transformation projects for various clients in Aviation, Machinery, Automotive, Food and Pharmaceuticals. You can connect with Dirk in the following ways: Website: www.mab-partners.com  LinkedIn: www.linkedin.com/in/dirkhorn Twitter @dirkhhorn   When I began the Drop in CEO Podcast, I knew that the best advice we could ever receive was from people who had been there. Now that we're over 50 episodes in, I thought it was time to pool some of the best advice into a collection that you could use to elevate your leadership and start putting humans first. You can download the full guide here: https://bit.ly/humancentrichero See omnystudio.com/listener for privacy information.

Jim Haney is Director, Supply Chain Customer Solutions in Johnson & Johnson’s Medical Devices sector.  In this role, Jim and his team collaborate with large health systems to drive operational efficiencies.   Jim has been with Ethicon since 1999, holding a variety of positions in Marketing, Account Management, Supply Chain and Health Economics & Market Access. Prior to joining Johnson & Johnson, Jim was a Corporate Accounts Director for Novartis Pharmaceuticals, responsible for contracting with managed care organizations to secure formulary status for Novartis’ branded pharmaceutical portfolio. Prior to Novartis, he worked as an Account Executive for Aetna, selling managed care plans to larger employers in a number of markets, to include Chicago and Pittsburgh. Jim is one of the many within Ethicon leading the charge in helping to bring insights into Ethicon's solutions and how they're bringing value to their customers. He's also utilizing the AIMeCAST platform to improve communication within his team and across the organization.  

Maryellen McQuade has been Corporate Vice President of Human Resources for Novo Nordisk Inc. since March 2017.She’s entrusted with cultivating and preserving the Novo Nordisk Way among the company’s people and culture.Ms. McQuade’s responsibilities encompass human resource strategies and programs that support the overall business, specifically in the areas of benefits, talent management, learning & development, diversity & inclusion, employee engagement and employee relations.With 13 years of pharmaceutical and human resource experience, Ms. McQuade’s expertise is primarily focused in business model redesign, organizational change, talent acquisition and management, and deepening managerial capabilities.  She is instrumental in maintaining a foundation of diverse and sophisticated talent, and a broad range of professional development resources, ensuring Novo Nordisk continues to be a place where people aspire to be, stay and grow. Ms. McQuade joined Novo Nordisk in 2016 as Vice President of Human Resources for Commercial Functions. Prior to that, she was the North America Human Resource Lead for Glaxo SmithKline (GSK) Consumer Health (a joint venture between Novartis Pharmaceuticals and GSK.) Before the merger between GSK and Novartis Pharmaceuticals, Ms. McQuade was the Global Human Resource Lead, Technical Operations & Quality at Novartis Pharmaceuticals.Previously, Ms. McQuade spent nearly 10 years at Bristol-Myers Squibb (BMS) in various roles of increasing responsibility in Human Resources, primarily working alongside the Research & Development functions. She ultimately led a Human Resource team supporting the BMS manufacturing network.Ms. McQuade sits on the board of trustees of the Princeton Charter School.  She holds a master’s degree from Georgetown University and a bachelor’s degree from Pomona College.

Overview The Stevens Group has been presenting the PR Masters Series Podcast for almost two years now.  This series is part of the ongoing partnership between The Stevens Group and CommPRO to bring to PR,digital/interactive and marketing communications agencies the wisdom of those who have reached the top of the PR profession.  Today's special guest is Denise Hill, Ph.D., APR Assistant Professor Elon University School of Communications.     About Our Guest Denise Hill is an assistant professor at Elon University's School of Communications, where she teaches undergraduate and graduate courses in strategic communications. Dr. Hill is a former chief communications officer with more than 30 years of corporate communications and public relations agency experience.  Before joining Elon University, Dr. Hill was vice president of corporate communications and public relations at Delhaize America, the U.S. operation of global Fortune 500 grocery retailer Delhaize Group. She previously held chief communication officer positions at Quest Diagnostics and a business unit of Wyndham Worldwide. In addition, she served as a vice president of communication at Novartis Pharmaceuticals and Cigna. She started her career at a Carl Byoir/Hill+Knowlton public relations agency in Philadelphia.  In addition to her Elon University teaching experience, Dr. Hill was an adjunct instructor of corporate communications and public relations at New York University. She also taught communications at the University of North Carolina at Chapel Hill.  She holds a bachelor's degree and master's degree in communications from Temple University, and a Ph.D. in mass communication from the University of North Carolina at Chapel Hill. Her academic research focuses on public relations and social change, how public relations was used to help marginalized groups in the United States gain civil rights, and African American public relations pioneers.  Dr. Hill is a member of the board of directors of the Public Relations Society of America. In addition, she is a member of the Arthur W. Page Society, where she serves on the new member liaison subcommittee. Dr. Hill is a member of the Association for Education in Journalism and Mass Communication, the American Journalism Historians Association, and an advisory board member of The Museum of Public Relations. She also serves on APCO Worldwide's International Advisory Council as a member of its Corporate Communications Strategies subgroup. Dr. Hill serves on the board of directors of Easterseals of North Carolina and Virginia, and she chairs the organization's development and communications committee. She is a former member of The Seminar, the premier organization of chief communication officers. She also is a former member of The Executive Leadership Council, the preeminent organization of African American business executives. 

Our guest is Robert Fukui. After obtaining his Bachelor's degree in Business with a concentration in Marketing from San Jose State University, Robert got his first sales job with the local Coca-Cola distributor straight out of college. After almost three years with Coca-Cola, he transitioned to the pharmaceutical industry, where he spent another 19 years with two major pharmaceutical companies in various types of sales, marketing, and training positions. He first worked for Novartis Pharmaceuticals and now most recently has spent 17 years with Bristol-Myers Squibb, one of the largest biopharmaceutical companies worldwide and among the industry leaders in HIV, Immuno-science and Oncology. Over the course of his professional career, he has been privileged to be instrumental in the launch of six major brands, responsible for over $150 million in revenue and a recipient of national sales and leadership development awards. His successful experience in product marketing through ever-changing economic conditions has positioned him to be able to assist local organizations to achieve sales success in any economic environment.

Episode 63, We interviewed Lynn Seth who is an experienced business leader, executive coach, keynote speaker and former collegiate Division I athlete, Lynn helps women ignite their personal power by unleashing their inner self-leader. The leader within each of us who practices habits that: Enhance Wellbeing Nurture Best-Self Optimize Performance Lynn brings her engaging and personable style to a global clientele list that includes Fortune 500 companies, nonprofit organizations and prominent academic institutions. In her work, Lynn brings her expertise in behavioral change; specifically focusing on helping women implement habits that align with the life they desire. Recently, Lynn had the opportunity to do such work in her role as a performance coach for Know Your Value; an MSNBC national tour that helped women share their personal purpose with the world. Prior to starting her consulting practice, Lynn spent over 20 years working in organizations such as WIC (Women, Infant and Children), Planned Parenthood, Parke-Davis, Warner- Lambert and most recently, Novartis Pharmaceuticals. Lynn’s educational background includes a bachelor’s degree from The University of Arizona and she holds two master’s degrees; a master’s in public health from The University of Arizona and a master’s in organizational development and leadership from The Fielding Institute. Lynn has been formally trained as an executive coach through CoachU, a certified International Coaching Federation institution. We Discuss: -According to HPI, “only 30% of American employees are engaged and performing to their full potential, and almost half are struggling to balance work and life” as a result of feeling pressure to always be “on.” Why is this such a problem in today’s society? What can women do to improve their careers, but also maintain balance in their personal lives? How does the Imposter Syndrome affect women vs. men? Women still seem to compete with one another, how can we better speak up and support one another? What are some of the most common obstacles seen with women in the workplace today? How can we overcome obstacles and position ourselves for success? Access Lynn's Free Ebook: Busy Living Solution System: The Busy living solution system is an introduction to unleashing the healthy, happy and best version of you! https://mail.google.com/mail/u/0?ui=2&ik=644ecaa6f0&attid=0.1&permmsgid=msg-f:1662259899412131162&th=171188924cd62d5a&view=att&disp=safe Connect with Lynn at Lead Her Solutions: LinkedIn: @Lynnseth Twitter: @leadherlive IG: Leadhersolutions FB: @Leadhersolutions Find Bev & Heather at: Instagram: BitchesBeBrave Facebook: Bitches Be Brave Website: www.bitchesbebrave.com. Email us at: Babesbebrave@gmail.com --- Send in a voice message: https://anchor.fm/bitchesbebrave/message

  The Stevens Group is pleased to present a new podcast series that salutes the masters of public relations and revels in their observations, insights and advice to PR professionals.  This new series is part of the ongoing partnership between The Stevens Group and CommPRO to bring to PR, digital/interactive and marketing communications agencies the wisdom of those who have reached the top of the PR profession.       About Our Guest Bob Pearson, Strategic Advisor, W2O Group Bob played a key role in building the 800-person firm, W2O Group, which is centered on algorithms, machine-learning and innovative media models that lead to insights-driven marketing communications campaigns.  He has served as Chief Technology Officer, President, Vice-Chairman and now Strategic Advisor.  Prior to W2O Group, Bob worked as VP of Communities and Conversations at Dell to develop the Fortune 500's first global social media function—an industry-leading approach to the use of social media, as highlighted in the best seller, GroundSwell. Before Dell, Bob was Head of Global Corporate Communications and Head of Global Pharma Communications at Novartis Pharmaceuticals in Basel, Switzerland, where he served on the Pharma Executive Committee and he held the role of Vice President of Media and Public Affairs for Rhone-Poulenc Rorer (now Sanofi).  He is an author, frequent speaker and blogger on digital marketing, as well as an adjunct professor at Syracuse University and The University of Texas McCombs School, where he is teaching a new course on digital media models.  He is a Visiting Scholar at The University of Southern California, where he will teach in the Fall of 2019.  Bob is also a guest lecturer at the U.S. State Department's Marketing College with a focus on digital media and how to counter disinformation and extremism.  He works in a digital media capacity as a contractor for OTI/USAID and the U.S. Agency for Global Media.    He has written two digital media books (PreCommerce and Storytizing) based on key learning's from the firm's work with innovative companies and individuals. Bob's third book, Countering Hate, co-authored with Haroon K. Ullah, explores how bias, hate and extremism forms, how we can counter it and what we can learn from extremist groups.  His fourth book with Kip Knight & Ed Tazzia, Crafting Persuasion, became available July 1, 2019.  Bob is now working on his first novel.  Bob currently serves on the boards of Vetted.org (vice-chair), The Advertising Research Foundation, Genprex, Inc., and as CEO of the MedicAlert Foundation.  He is on the KPMG digital advisory board and is a member of the Defense Science Board for the Department of Defense.  Bob resides in Austin, Texas.  

 In this episode of Motivated to Lead podcast we interview Rich Dilorio,  who is the President and CEO of InfuSystem (NYSE American:INFU). Rich shares lessons learned in his career and as a CEO.  Rich brings a strong track record of accomplishment with more than 17 years of medical sales experience, extensive expertise in product launch, and industry knowledge focused on driving growth in the oncology market. During Rich's 13-year tenure with InfuSystem, he has received numerous awards and honors. Prior to joining the Company, Mr. Dilorio held various sales and sales leadership roles at Stryker Medical, Novartis Pharmaceuticals, and Thermo Scientific. He earned a Bachelor of Science degree in Biology from Boston College.

1.Quality of Life Outcomes in Patients Presenting for Evaluation of Central Nervous System Tumors 2. [What’s Trending]: 'Landmark study’ shows brain cells revamp their DNA, perhaps sparking Alzheimer’s disease. In the first segment, Dr. Ted Burns talks with Dr. Irene Katzan about her paper on quality of life outcomes in patients presenting for evaluation of central nervous system tumors. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Jerold Chun on a 'Landmark study’ showing brain cells revamp their DNA, perhaps sparking Alzheimer’s disease.Dr. Ted Burns has served on scientific advisory boards for Argenx, Momenta, received travel funding or speaker honoraria from Argenx, Alexion and received support for consulting activities from UCB Pharma, CSL Behring, Momenta, Argenx. Dr. Irene Katzan has served on editorial boards for Stroke (American Stroke Association), 2014-present Editorial Board - Circulation: Cardiovascular Quality & Outcomes (American Heart Association) 2013 – present. Dr. Irene Katzan has received research from one commercial entity including Novartis Pharmaceuticals and received research support from the following government entity: Ohio Department of Health - Physician Lead for the Ohio Paul Coverdell Stroke Registry, 2007-2020. Dr. Burns has served on the DSMB for NIH-funded trials (non-profit entities); serves on the editorial board for Journal of Alzheimer's Disease; has consulted for Grifols, USA; has served on Eli Lilly Amyvid Speaker's Bureau; and has received research support from Eli Lilly, Avid Radiopharmaceuticals, Toyama Chemical Company, Merck, Biogen, AbbVie, Novartis, vTv Therapeutics, Janssen, and NIH (R01AG058557, R01AG053312, R01AG034614, R01AG03367, R01AG043962, P30AG035982, U10NS077356, UL1TR000001).Dr. Jerold Chun reports no disclosures.

1. Patient-reported outcomes across cerebrovascular event types - more similar than different 2. [What’s Trending]: Genetic landscape of pediatric movement disorders and management implications.In the first segment, Dr. Andrew Southerland talks with Dr. Irene Katzan about her paper on patient-reported outcomes across cerebrovascular event types. In the second part of the podcast, Dr. Jeff Waugh focuses his interview with Dr. Saadet Andrews on the genetic landscape of pediatric movement disorders and management implications. DISCLOSURES: Dr. Southerland has severed on editorial boards for the Journal Neurology and is Section Editor for the Neurology Podcast. Dr. Katzan served on editorial boards for Stroke (American Stroke Association) and Circulation: Cardiovascular Quality & Outcomes (American Heart Association). Dr. Katzan has received funding for research support from Novartis Pharmaceuticals and research support from the Ohio Department of Health - Physician Lead for the Ohio Paul Coverdell Stroke Registry, 2007-2020. Dr. Waugh was employed by Children's Hospital Boston, Resident in Pediatric Neurology, 2009-2015. Dr.Saadet Andrews served on a scientific advisory board for non-profit data safety board member for a research study at The Hospital for Sick Children (2015-2017), a Commercial: Epileptic encephalopathy scientific board meeting attended in December 2017, organized by BioMarin, and a Commercial: Advisor cost effectiveness of ERT (March 2018) Commercial: Advisory board and speaker for homocysteine and betaine treatment (December 2017). Dr. Andrews received funding for travel from BioMarin (Epileptic encephalopathy scientific board meeting attended as invited speaker in December 2017) and was paid honorarium and travel-expenses. Dr. Andrews served on editorial boards for Non-profit: Journal of Pediatric Genetics Editorial Board Member (2015-present) and received research support from industry funding (2015-2016) for prevalence of mucopolysaccharidosis if rheumatology and NCV patients.

Prior to Aventria, David held several commercial leadership roles, including Head of Oncology Marketing at Genentech and VP Strategic Marketing at Schering AG, specializing in commercializing oncology and specialty products. He was also instrumental in the commercialization of Taxotere, Fludara, Herceptin, and Rituxan. Paul has extensive experience leading successful market access commercialization strategies of specialty pharmaceuticals throughout their life cycles, including several landmark oncology products and other specialty therapeutics. Paul is a former Vice President of Payer Marketing with Bayer and former Vice President and Head of Oncology Managed Markets and Market Access at Novartis Pharmaceuticals. He is an RPh and a graduate of Rutgers University's Ernest Mario College of Pharmacy. 00:00 The trends affecting market access to oncology. 02:00 Innovations in oncology. 02:20 Immuno-oncology. 03:50 How treatment has improved with these oncology innovations. 05:45 The implications of patients getting access to these new treatment options. 07:20 Answering 3 questions around these oncology innovations. 10:05 Outcomes-based contracts and biomarker testing. 11:30 Risk-based contracts. 12:15 Indication-based pricing 14:45 “How do we make access to novel specialty drugs more affordable for the actual patient.” - Paul Pochtar 17:50 How various biomarkers fit in together. 18:15 Determining what biomarkers are relevant. 19:00 Pathways and guidelines being derived from Real World Evidence. 20:45 “There's no standardized approach.” - David Guy 23:40 How a pathway gets used. 29:35 Alternative payment models. 30:15 “As we look for a solution, it's not one entity that has the answer.” - Paul 30:45 Innovation, cost challenge, decision-making process. 32:38 “The elephant in the room is the co-pay burdens.” - David 32:57 Why is a co-pay applicable for a cancer patient? 33:33 Andrew Schorr of Patient Power - EP145.

This Product Theater, sponsored by Novartis Pharmaceuticals, from the SDPA 14th Annual Fall Dermatology Conference 2016, held November 3 – 6 in Las Vegas, Nevada, titled “COSENTYX (secukinumab) for the Ongoing Management of Adult Patients with Moderate to Severe Plaque Psoriasis and Active Psoriatic Arthritis” was presented by Clive Liu, MD.

Originally recorded during a panel session at the 2017's Immuno-Oncology 360°, Mark Simon of Torreya Partners moderates the conversation around issues, controversies, and other important business aspects of IO. He's joined by IO360° lead advisor and SVP at GSK, Dr Axel Hoos, Dr Robert Ang of Neon Therapeutics, Dr Jeffrey Bockman from Defined Health, Dr Jeffrey Legos from Novartis Pharmaceuticals, and Dr Chandra Ramanathan at Bayer Healthcare. Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.

Julie Austin, Creative Innovation Group, is an award-winning author, inventor, futurist, innovation speaker, and member of the World Future Society. She’s an internationally known thought leader on the topic of innovation, and CEO of the consulting firm Creative Innovation Group. She’s been a keynote innovation speaker for corporations such as Procter & Gamble, Novartis Pharmaceuticals, Northrop Grumman, and Cognizant Technology Solutions. She’s also been featured in the books “Patently Female” and “Girls Think of Everything”. Her patented product, swiggies, wrist water bottles, have been a NASDAQ product of the year semi finalist and are currently sold in 24 countries. Julie and her products have appeared on The Today Show, The Queen Latifa Show, HGTV, Lifetime, ABC, CBS, NBC, FOX News, Inc. magazine, Fast Company, and the Wall Street Journal, along with dozens of TV shows, magazines and radio shows around the world.

Bob Pearson is the President of the W2O Group, a group of 3 marketing and communications companies. Prior to working at the W2O Group, Bob Pearson was the Vice President of Communities and Conversation for Dell, where he developed their first global social media efforts. Bob also worked as Head of Global Corporate Communications for Novartis Pharmaceuticals. Bob recently wrote Storytizing: What's Next After Advertising?, where he explores how messages proliferate through society. Bob is also a frequent speaker on digital marketing at the Syracuse Center for Social Commerce and the U.S. State Department's Marketing College. In this episode, you'll learn how to find the people who drive the majority of conversation, easy quick wins for government and public sector communicators, which no one can object to, and why 43 people drive the majority of shared conversation for Harry Potter. Hosted on Acast. See acast.com/privacy for more information.

Bob Pearson is the President of the W2O Group, a group of 3 marketing and communications companies. Prior to working at the W2O Group, Bob Pearson was the Vice President of Communities and Conversation for Dell, where he developed their first global social media efforts. Bob also worked as Head of Global Corporate Communications for Novartis Pharmaceuticals. Bob recently wrote Storytizing: What's Next After Advertising?, where he explores how messages proliferate through society. Bob is also a frequent speaker on digital marketing at the Syracuse Center for Social Commerce and the U.S. State Department’s Marketing College. In this episode, you'll learn how to find the people who drive the majority of conversation, easy quick wins for government and public sector communicators, which no one can object to, and why 43 people drive the majority of shared conversation for Harry Potter.

The drug Ritalin was originally used as a stimulant for adults - until researchers discovered it could help children concentrate. It's now taken by millions of patients around the world to treat Attention Deficit Hyperactivity Disorder or ADHD.Witness speaks to Dr C Keith Conners, one of the researchers behind the first randomised clinical trial of Ritalin on children in 1964.PICTURE: Ritalin blister-packs and packet. Ritalin is a proprietary brand of Novartis Pharmaceuticals. Copyright Science Photo Library.

The drug Ritalin was originally used as a stimulant for adults - until researchers discovered it could help children concentrate. It's now taken by millions of patients around the world to treat Attention Deficit Hyperactivity Disorder or ADHD. Witness speaks to Dr C Keith Conners, one of the researchers behind the first randomised clinical trial of Ritalin on children in 1964. PICTURE: Ritalin blister-packs and packet. Ritalin is a proprietary brand of Novartis Pharmaceuticals. Copyright Science Photo Library.

Paul Pochtar is an industry leader who has more than 25 years of extensive experience leading the successful commercialization of specialty pharmaceuticals throughout their lifecycle, including several landmark oncology products and other specialty therapeutics. He has been instrumental in developing innovative brand value propositions that resonate with government and commercial payers and in the execution of market introductions by designing novel distribution, dispensing, and patient services models. He has strong operational proficiency and a keen ability to mobilize both Pharma functional skill centers and channel partners to build plans, structures, and processes to efficiently execute strategies. Paul has enjoyed a distinguished career with Bayer Pharmaceuticals as Vice President of Payer Marketing and with Novartis Pharmaceuticals as Vice President & Head of Oncology Managed Markets and Market Access. He is a graduate of Rutgers University Ernest Mario College of Pharmacy and is a registered pharmacist in New Jersey and Pennsylvania. He can be reached at paulpochtar@gmail.com 00:00 Paul discusses the changes in the healthcare industry from the Pharma viewpoint.01:15 Paul breaks down these changes step by step.02:10 How these changes are impacting Pharma on a larger scale.03:30 What failure means in the Pharma perspective.04:25 The issue of needing clear criteria.05:35 From the Pharma perspective, why companies need to be laying out very strong value proposition.06:30 From the Pharma perspective, companies need to be laying out a very strong value proposition.07:40 The right balance of the marketing mix, and what this is for Pharma business in healthcare.08:35 “Copay is all about supply and demand.”09:40 The need to think about the business Pharma is truly in, in order to improve patient care.10:15 Paul discusses successful and non-successful business models that he has come across over the years.11:40 Paul talks about some of the advanced formulary decision-making criteria for clinical trials hoping to get FDA approval.14:50 Patient population and how this fluctuates according to the data that a Pharma company has.16:50 How Pharma is equipped to work with the constant change of decision-makers within healthcare.18:00 Consolidation within Pharma and how it benefits patient care and healthcare in general.21:15 How hospitals are changing their infrastructures with population in mind.23:20 Paul gives his advice to Pharma organizations attempting to navigate their businesses.24:00 The four things Pharma needs to consider when a manufacturer wants to change.24:30 Why a comprehensive strategy is most important in considering change within a Pharma company.27:00 Engaging high-risk patients.30:00 Which organizations need consideration for having a different collaborating relationship with patients, and how patients are really struggling in the marketplace.

In this podcast, Dr. Paul Yamauchi and Novartis Pharmaceuticals share information on the pathophysiology of psoriasis and advancing doctor-patient dialogue. This lecture was recorded at the SDPA 2014 Fall Conference in San Diego.

Since the FDA and EMA published their current thinking on clinical oversight and risk-based monitoring (RBM) strategies, the topic has received a magnitude of attention, commanding column inches, webinar discussions and industry conferences. With so much discussion going on, it is unsurprising that many sponsors are feeling out in the cold when it comes to identifying how to practically implement RBM strategies within study designs. As data quality matters most in determining study success and ensuring patient safety, the latest recommendations have created growing demand for solutions that simplify the transition to risk-based techniques. In this program, our guests discuss how emerging technologies and Central Statistical Monitoring (CSM) now present more practical means of implementing successful RBM strategies. Both Sanofi and Novartis will provide a large pharma perspective on making the move to RBM. Host: Valerie Bowling, Executive Director, The Conference Forum Guests: Marc Buyse, Founder, International Drug Development Institute & CluePoints Eric Genevois-Marlin, VP, Biostatistics & Programming, Sanofi Thomas Haag, Data Integrity Process Expert, eClinical Quality Assurance, Novartis Pharmaceuticals    

Combining the power of video and social media. Jerry will answer CF-related questions in a short format video.Made possible by Novartis Pharmaceuticals.In the third and final installment of our "Transitions" series, we meet Gabriella. For Gabriella, transitioning from college to the career world had lots of similarities, particularly regarding the need for a disciplined compliance schedule.  Still, one fear lingered over her: what happens when I get sick? Gabriella's fears were realized twice, but she found herself more than pleasantly surprised by the support of her co-workers.For more information about cystic fibrosis or the Boomer Esiason Foundation, be sure to visit our website at www.esiason.org

Combining the power of video and social media. Jerry will answer CF-related questions in a short format video.Made possible by Novartis Pharmaceuticals. In this second part of a three-part series on transitions, we meet Ryan Randazzo. Like many kids his age, Ryan wanted to go out of state for college. But after weighing his options, he decided on the State University of New York at New Paltz, staying close to a CF center in case of an emergency. Ryan talks about the challenges of transitioning from high school to college, especially as it pertains to adjusting to a new schedule. He says some colleges will be flexible and accommodating to the needs of CF patients, but you should be sure to consult with your college about those options. Soon after getting to SUNY - New Paltz, Ryan was on his own, and very quickly learned the importance of maintaining your own schedule and having self-discipline when it comes to compliance. If you know you can go away to school with cystic fibrosis, he says, you can do anything in life. For more information about cystic fibrosis or the Boomer Esiason Foundation, be sure to visit our website at www.esiason.org

Combining the power of video and social media. Jerry will answer CF-related questions in a short format video.Made possible by Novartis Pharmaceuticals.This is the first in a three-part CF Wind Sprint series which will take a look at the major transitioning stages for people with cystic fibrosis. In this episode, we meet Jillian Monitello, a native of Long Island, NY. Jillian candidly opens up about her experience in transitioning from pediatric CF care to adult CF care. Jillian shares a few tips about making that transition, and recalls the stress she felt when first told she would need to move into adult CF care. In the end, thanks to the guidance of her doctors, hers was a smooth transition.For more information about cystic fibrosis or the Boomer Esiason Foundation, be sure to visit our website at www.esiason.org

Guest: Jacqueline Pongracic, MD Host: Bill Rutenberg, MD Our guest, Dr. Jacqueline Pongracic is the co-investigator of the Inner City Asthma Study sponsored by the NIH and Novartis Pharmaceuticals. In this segment, Dr. Pongracid speaks with host, Dr. Bill Rutenberg about the objectives of the study and the study protocol.